[Expression of YKL-40 and TLR4 in patients with chronic rhinosinusitis].
Jinan, China. In Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi, Apr 2015
OBJECTIVE: To explore the expression of YKL-40, TLR4 and NF-κB in chronic rhinosinusitis (CRS) with or without nasal polyps (CRSwNP and CRSsNP), and to investigate their expressional correlation and the potential role in pathogenesis of CRS.
OSAS-related inflammatory mechanisms of liver injury in nonalcoholic fatty liver disease.
Torino, Italy. In Mediators Inflamm, Dec 2014
In this review, we focus on molecular mechanisms linking OSAS to NAFLD, including hypoxia inducible factor (HIF), nuclear factor kappa B (NF-κB), YKL-40, unfolded protein response, and hypoxic adipose tissue inflammation, which all could provide novel potential therapeutic approaches for the management of NAFLD patients with OSAS.
Biomarkers of progression of chronic obstructive pulmonary disease (COPD).
Brisbane, Australia. In J Thorac Dis, Nov 2014
Examples of peripheral blood biological markers (biomarkers) include those associated with lung function (reduced CC-16), emphysema severity (increased adiponectin, reduced sRAGE), exacerbations and mortality [increased CRP, fibrinogen, leukocyte count, IL-6, IL-8, and tumor necrosis factor α (TNF-α)] including increased YKL-40 with mortality.
Biomarkers in connective tissue disease-associated interstitial lung disease.
Essen, Germany. In Semin Respir Crit Care Med, Apr 2014
Promising biomarkers are lung epithelium-derived proteins such as KL-6 (Krebs von den Lungen-6), SP-D (surfactant protein-D), SP-A (surfactant protein-A), YKL-40 (chitinase-3-like protein 1 [CHI3L1] or cytokines such as CCL18 [chemokine (C-C) motif ligand 18]).
Unveiling YKL-40, from Serum Marker to Target Therapy in Glioblastoma.
New York City, United States. In Front Oncol, 2013
We review the current concept of developing YKL-40 as one of the most promising serum markers for glioblastoma, the recent advances on understanding the role of YKL-40 in gliomagenesis, and the promising evidence emerging from preclinical models on using this protein as a target for anti-glioma therapy.